Adjunctive corticosteroid therapy is safe for bacterial corneal ulcers

Article

Using adjunctive corticosteroid therapy is safe on bacterial corneal ulcers and does not alter best spectacle-corrected visual acuity (BSCVA)Using adjunctive corticosteroid therapy is safe on bacterial corneal ulcers and does not alter best spectacle-corrected visual acuity (BSCVA).

Using adjunctive corticosteroid therapy is safe on bacterial corneal ulcers and does not alter best spectacle-corrected visual acuity (BSCVA), claims a study in the Archives of Ophthalmology.

Dr Muthiah Srinvasan and his team, Department of Corneal and External Diseases, Aravind Eye Care System, Madurai, India, conducted a randomized, placebo-controlled, double-masked multicentered clinical trial on 1769 patients with bacterial corneal ulcers. All patients were screened between September 1, 2006 and February 22, 2010.

The primary outcome was BSCVA at 3 months from patient enrolment and the secondary outcomes were infiltrate/scar size, re-epithelialization and corneal perforation.

In the subgroups of baseline BSCVA and ulcer location there were a significant number of corticosteroids observed. There was no significant difference in the 3-month BSCVA infiltrate scar/size, time to re-epithelialization and corneal perforation.

Patients with vision of counting fingers or worse at baseline presented with 0.17 logMAR better visual acuity with corticosteroids. Patients that were at baseline had 0.20 logMAR better visual acuity with corticosteroids.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.